Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report)'s share price crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.52 and traded as high as $3.60. Regulus Therapeutics shares last traded at $3.37, with a volume of 2,201,107 shares.
Analyst Ratings Changes
Several research firms have recently commented on RGLS. Jones Trading reissued a "hold" rating and issued a $7.00 price target (down from $8.00) on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. Wells Fargo & Company restated an "equal weight" rating and issued a $9.00 target price on shares of Regulus Therapeutics in a research note on Thursday. Leerink Partnrs lowered Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. HC Wainwright restated a "buy" rating and set a $10.00 target price on shares of Regulus Therapeutics in a research note on Friday, March 14th. Finally, Leerink Partners reaffirmed a "market perform" rating and set a $7.00 target price on shares of Regulus Therapeutics in a research report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $8.50.
Get Our Latest Stock Analysis on RGLS
Regulus Therapeutics Price Performance
The firm has a market capitalization of $518.35 million, a price-to-earnings ratio of -7.31 and a beta of 1.03. The business has a fifty day moving average price of $2.11 and a two-hundred day moving average price of $1.66.
Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last released its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20). During the same quarter in the previous year, the company earned ($0.40) earnings per share. On average, research analysts predict that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.
Institutional Trading of Regulus Therapeutics
Hedge funds have recently modified their holdings of the stock. Octagon Capital Advisors LP lifted its holdings in Regulus Therapeutics by 13.7% in the fourth quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company's stock valued at $7,661,000 after acquiring an additional 585,101 shares during the period. Millennium Management LLC grew its position in Regulus Therapeutics by 69.7% during the fourth quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock valued at $3,464,000 after buying an additional 900,743 shares during the period. JPMorgan Chase & Co. increased its holdings in Regulus Therapeutics by 141.2% in the fourth quarter. JPMorgan Chase & Co. now owns 190,457 shares of the biopharmaceutical company's stock valued at $301,000 after buying an additional 111,485 shares in the last quarter. Tyche Wealth Partners LLC raised its position in shares of Regulus Therapeutics by 14.6% in the first quarter. Tyche Wealth Partners LLC now owns 121,589 shares of the biopharmaceutical company's stock worth $213,000 after acquiring an additional 15,500 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in shares of Regulus Therapeutics by 20.5% during the 4th quarter. Renaissance Technologies LLC now owns 117,100 shares of the biopharmaceutical company's stock worth $185,000 after acquiring an additional 19,900 shares in the last quarter. Hedge funds and other institutional investors own 92.38% of the company's stock.
About Regulus Therapeutics
(
Get Free Report)
Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.
Further Reading
Before you consider Regulus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regulus Therapeutics wasn't on the list.
While Regulus Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
